Earkart manufactures and distributes hearing aids and diagnostic equipment, primarily serving ENT clinics and government agencies in India through a tech-enabled shop-in-shop model.
The company possesses a narrow moat based on its patented OMNI diagnostic device, which enables remote audiometry in underserved regions. However, high average ROCE is contradicted by negative cash conversion and a heavy reliance on lumpy government contracts, suggesting the technology advantage hasn't yet translated into durable financial strength.
Capital has been primarily directed toward R&D for the OMNI platform and aggressive expansion into ENT clinics. While revenue growth is high, the recent IPO proceeds are being used to fund working capital and infrastructure, with a notable lack of dividend history or share buybacks.
The company's aggressive revenue growth proved to be a mirage of uncollectible paper profits as receivable days ballooned beyond repair. By relying on lumpy government contracts and ignoring the deteriorating cash conversion, the firm eventually faced a liquidity crisis that forced dilutive financing. The OMNI device, while patented, failed to provide a sustainable barrier against larger medical device competitors, and the management's history of regulatory lapses and promoter-related financial entanglements eventually eroded shareholder trust, leading to a permanent re-rating of the stock.
RichFakir rates Earkart Limited's business quality as mediocre — 41/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Earkart Limited is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Earkart Limited is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Earkart Limited's fair value is about ₹42 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →